Equities research analysts forecast that Imperva Inc (NASDAQ:IMPV) will report $91.18 million in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Imperva’s earnings, with estimates ranging from $90.48 million to $92.00 million. Imperva reported sales of $78.40 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 16.3%. The business is expected to announce its next earnings results on Wednesday, February 14th.
On average, analysts expect that Imperva will report full-year sales of $91.18 million for the current fiscal year, with estimates ranging from $321.00 million to $322.64 million. For the next year, analysts anticipate that the business will report sales of $377.16 million per share, with estimates ranging from $369.00 million to $383.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Imperva.
Imperva (NASDAQ:IMPV) last announced its earnings results on Wednesday, November 8th. The software maker reported $0.33 EPS for the quarter, topping the consensus estimate of $0.22 by $0.11. The firm had revenue of $83.89 million for the quarter, compared to the consensus estimate of $83.79 million. Imperva had a net margin of 3.04% and a negative return on equity of 8.52%. The business’s quarterly revenue was up 22.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.08 EPS.
Imperva (NASDAQ:IMPV) traded down $0.20 during midday trading on Friday, reaching $42.40. 84,709 shares of the company’s stock traded hands, compared to its average volume of 246,163. The firm has a market cap of $1,440.00, a price-to-earnings ratio of 157.04 and a beta of 1.78. Imperva has a 52 week low of $37.17 and a 52 week high of $52.40.
A number of large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its stake in shares of Imperva by 1,235.5% during the second quarter. Russell Investments Group Ltd. now owns 9,188 shares of the software maker’s stock worth $440,000 after buying an additional 8,500 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Imperva by 10.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 131,762 shares of the software maker’s stock worth $6,305,000 after buying an additional 12,287 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Imperva by 9.8% during the second quarter. Rhumbline Advisers now owns 37,916 shares of the software maker’s stock worth $1,814,000 after buying an additional 3,387 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Imperva by 8.5% during the second quarter. Bank of New York Mellon Corp now owns 136,025 shares of the software maker’s stock worth $6,509,000 after buying an additional 10,627 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in Imperva by 27.2% during the second quarter. Legal & General Group Plc now owns 13,545 shares of the software maker’s stock valued at $649,000 after purchasing an additional 2,894 shares during the period. Hedge funds and other institutional investors own 96.93% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Analysts Expect Imperva Inc (IMPV) Will Announce Quarterly Sales of $91.18 Million” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/05/analysts-expect-imperva-inc-impv-will-announce-quarterly-sales-of-91-18-million.html.
Imperva Company Profile
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.